Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viatris IncVTRS · Entity 3277 | Director | March 06, 2025 | March 10, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viatris Inc
Report date March 06, 2025 · Filed March 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 23,660 |
Reported balance
After 2025-03-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-06 · Grant · Acquired 23,660 · Balance 23,660 F1: As previously disclosed on October 20, 2023, the reporting person informed Viatris Inc. ("Viatris") of his intention to retire from his executive role with Viatris effective as of April 1, 2024 and agreed to remain a member of Viatris' Board of Directors. As a non-employee director, the reporting person is eligible to participate in Viatris' non-employee director compensation program. Represents restricted stock units (RSUs) granted for such service, consistent with the grants provided to Viatris' other non-employee directors. F2: Each RSU represents the right to receive one share of common stock of Viatris. These RSUs will vest on March 6, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: As previously disclosed on October 20, 2023, the reporting person informed Viatris Inc. ("Viatris") of his intention to retire from his executive role with Viatris effective as of April 1, 2024 and agreed to remain a member of Viatris' Board of Directors. As a non-employee director, the reporting person is eligible to participate in Viatris' non-employee director compensation program. Represents restricted stock units (RSUs) granted for such service, consistent with the grants provided to Viatris' other non-employee directors.
F2: Each RSU represents the right to receive one share of common stock of Viatris. These RSUs will vest on March 6, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mylan II B.V.
Report date November 16, 2020 · Filed November 18, 2020
Section 16 reporting ended · disclosed 2020-11-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-11-16 · Disposition to issuer · Disposed 459,699 · Balance 0 F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2: 28,546 ordinary shares were returned to the reporting person's direct beneficial ownership on November 10, 2020 in the form of a scheduled annuity payment under the terms of the grantor retained annuity trust to which the reporting person initially contributed 100,000 ordinary shares on October 23, 2018 and 161,635 ordinary shares were returned to the reporting person's direct beneficial ownership on November 11, 2020 in the form of a scheduled annuity payment under the terms of the grantor retained annuity trust to which the reporting person initially contributed 250,000 ordinary shares on September 18, 2019. F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Grantor Retained Annuity Trust | 0 |
Reported balance
After 2020-11-16 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-11-16 · Disposition to issuer · Disposed 88,365 · Balance 0 F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $55.84 · Expires 2024-03-05 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-16 · Disposition to issuer · Disposed 34,389 · Balance 0 F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F5: These options vested on March 5, 2017. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $50.66 · Expires 2025-11-17 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-16 · Disposition to issuer · Disposed 41,637 · Balance 0 F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F6: These options vested on March 4, 2018. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $46.27 · Expires 2026-02-17 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-16 · Disposition to issuer · Disposed 50,168 · Balance 0 F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F7: These options vested on February 17, 2019. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $45.18 · Expires 2027-03-03 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-16 · Disposition to issuer · Disposed 65,574 · Balance 0 F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F8: These options vested on March 3, 2020. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $40.97 · Expires 2028-03-02 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-16 · Disposition to issuer · Disposed 71,600 · Balance 0 F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F9: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $27.45 · Expires 2029-03-01 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-11-16 · Disposition to issuer · Disposed 60,053 · Balance 0 F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F14: 20,018 of these options vested on March 2, 2020, 20,017 will vest on March 2, 2021 and 20,018 will vest on March 2, 2022. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $17.48 · Expires 2030-03-02 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2020-11-16 · Disposition to issuer · Disposed 84,871 · Balance 0 F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F17: 28,291 of these options will vest on March 2, 2021 and 28,290 will vest on each of March 2, 2022 and March 2, 2023. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-11-16 · Disposition to issuer · Disposed 14,645 · Balance 0 F9: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021. F10: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F11: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-11-16 · Disposition to issuer · Disposed 67,031 · Balance 0 F9: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021. F10: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F15: Each RSU represents the right to receive one ordinary share of Mylan. 33,515 of the RSUs will vest on March 2, 2021 and 33,516 will vest on March 2, 2022. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2020-11-16 · Disposition to issuer · Disposed 157,895 · Balance 0 F9: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021. F10: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F18: Each RSU represents the right to receive one ordinary share of Mylan. 52,632 of the RSUs will vest on March 2, 2021, 52,631 will vest on March 2, 2022 and 52,632 will vest on March 2, 2023. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 73,225 |
Reported balance
After 2020-11-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-11-16 · Grant · Acquired 73,225 · Balance 73,225 F12: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-11-16 · Disposition to issuer · Disposed 73,225 · Balance 0 F12: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. F13: Represents PRSUs of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms (other than no longer being subject to the performance-based vesting conditions) in connection with the Combination. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 125,684 |
Reported balance
After 2020-11-16 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2020-11-16 · Grant · Acquired 125,684 · Balance 125,684 F16: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 1, 2019, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2020-11-16 · Disposition to issuer · Disposed 125,684 · Balance 0 F12: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. F13: Represents PRSUs of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms (other than no longer being subject to the performance-based vesting conditions) in connection with the Combination. F16: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 1, 2019, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 197,369 |
Reported balance
After 2020-11-16 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2020-11-16 · Grant · Acquired 197,369 · Balance 197,369 F19: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2020, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2020-11-16 · Disposition to issuer · Disposed 197,369 · Balance 0 F12: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. F13: Represents PRSUs of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms (other than no longer being subject to the performance-based vesting conditions) in connection with the Combination. F19: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2020, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).
F2: 28,546 ordinary shares were returned to the reporting person's direct beneficial ownership on November 10, 2020 in the form of a scheduled annuity payment under the terms of the grantor retained annuity trust to which the reporting person initially contributed 100,000 ordinary shares on October 23, 2018 and 161,635 ordinary shares were returned to the reporting person's direct beneficial ownership on November 11, 2020 in the form of a scheduled annuity payment under the terms of the grantor retained annuity trust to which the reporting person initially contributed 250,000 ordinary shares on September 18, 2019.
F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.
F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination.
F5: These options vested on March 5, 2017.
F6: These options vested on March 4, 2018.
F7: These options vested on February 17, 2019.
F8: These options vested on March 3, 2020.
F9: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021.
F10: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination.
F11: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021.
F12: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination.
F13: Represents PRSUs of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms (other than no longer being subject to the performance-based vesting conditions) in connection with the Combination.
F14: 20,018 of these options vested on March 2, 2020, 20,017 will vest on March 2, 2021 and 20,018 will vest on March 2, 2022.
F15: Each RSU represents the right to receive one ordinary share of Mylan. 33,515 of the RSUs will vest on March 2, 2021 and 33,516 will vest on March 2, 2022.
F16: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 1, 2019, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination.
F17: 28,291 of these options will vest on March 2, 2021 and 28,290 will vest on each of March 2, 2022 and March 2, 2023.
F18: Each RSU represents the right to receive one ordinary share of Mylan. 52,632 of the RSUs will vest on March 2, 2021, 52,631 will vest on March 2, 2022 and 52,632 will vest on March 2, 2023.
F19: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2020, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2020 Filed Mar 4, 2020 18:41 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 14,645 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-007035 · doc4.xml · nonDerivative · entry 1 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: 127,008 ordinary shares were returned to the reporting person's direct beneficial ownership on September 17, 2019 in the form of a scheduled annuity payment under the terms of the grantor retained annuity trust to which the reporting person initially contributed 250,000 ordinary shares on September 5, 2017. F2 · balance_after: 71,454 ordinary shares were returned to the reporting person's direct beneficial ownership on January 27, 2020 in the form of a scheduled annuity payment under the terms of the grantor retained annuity trust to which the reporting person initially contributed 100,000 ordinary shares on October 23, 2018. F3 · balance_after: On September 18, 2019, the reporting person contributed 250,000 ordinary shares of Mylan N.V. to a grantor retained annuity trust of which the reporting person is the sole trustee and sole annuitant. Read SEC document |
| March 03, 2019 Filed Mar 5, 2019 18:11 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 12,395 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006201 · doc4.xml · derivative · entry 11 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,395 Underlying: Ordinary Shares · 12,395 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 12,395 of the RSUs granted on March 3, 2017 vested on each of March 3, 2018 and March 3, 2019, and 12,395 will vest on March 3, 2020. F7 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 12,395 of the RSUs granted on March 3, 2017 vested on each of March 3, 2018 and March 3, 2019, and 12,395 will vest on March 3, 2020. Read SEC document |
| March 03, 2019 Filed Mar 5, 2019 18:11 UTC | Mylan II B.V. MYL · Entity 16217 | Tax withholdingOrdinary Shares | 5,471 | $27.45 | $150,178.95 |
DisclosureSEC source: 0000899243-19-006201 · doc4.xml · nonDerivative · entry 5 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,917 F3 · shares: Represents withholding of ordinary shares for the tax liability associated with the vesting and settlement of a portion of the RSUs granted on March 3, 2017. Read SEC document |
| March 03, 2019 Filed Mar 5, 2019 18:11 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 12,395 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006201 · doc4.xml · nonDerivative · entry 4 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2019 Filed Mar 5, 2019 18:11 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 14,645 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006201 · doc4.xml · derivative · entry 10 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,290 Underlying: Ordinary Shares · 14,645 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 14,645 of the RSUs granted on March 2, 2018 vested on March 2, 2019, and 14,645 will vest on each of March 2, 2020 and March 2, 2021. F6 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 14,645 of the RSUs granted on March 2, 2018 vested on March 2, 2019, and 14,645 will vest on each of March 2, 2020 and March 2, 2021. Read SEC document |
| March 02, 2019 Filed Mar 5, 2019 18:11 UTC | Mylan II B.V. MYL · Entity 16217 | Tax withholdingOrdinary Shares | 6,464 | $27.45 | $177,436.80 |
DisclosureSEC source: 0000899243-19-006201 · doc4.xml · nonDerivative · entry 3 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,993 F2 · shares: Represents withholding of ordinary shares for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on March 2, 2018. Read SEC document |
| March 02, 2019 Filed Mar 5, 2019 18:11 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 14,645 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006201 · doc4.xml · nonDerivative · entry 2 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 18:11 UTC | Mylan II B.V. MYL · Entity 16217 | GrantRestricted Stock Units · Derivative | 100,547 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006201 · doc4.xml · derivative · entry 9 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,547 Underlying: Ordinary Shares · 100,547 shares Expires not disclosed F5 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 33,516 of the RSUs will vest on March 2, 2020, 33,515 will vest on March 2, 2021, and 33,516 will vest on March 2, 2022. F5 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 33,516 of the RSUs will vest on March 2, 2020, 33,515 will vest on March 2, 2021, and 33,516 will vest on March 2, 2022. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 18:11 UTC | Mylan II B.V. MYL · Entity 16217 | GrantEmployee Stock Option - Right to Buy · Derivative | 60,053 | $0.00 Strike: $27.45 | $0.00 |
DisclosureSEC source: 0000899243-19-006201 · doc4.xml · derivative · entry 8 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,053 Underlying: Ordinary Shares · 60,053 shares Expires 2029-03-01 F4 · derivative.exercise_date: 20,018 of the options will vest on March 2, 2020, 20,017 will vest on March 2, 2021, and 20,018 will vest on March 2, 2022. The options expire on March 1, 2029. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 18:11 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerOrdinary Shares | 324,061 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006201 · doc4.xml · nonDerivative · entry 1 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,812 F1 · shares: Represents forfeiture of unvested restricted ordinary shares received under the One-Time Special Performance-Based Five-Year Realizable Value Incentive Program as a result of the applicable performance conditions not having been met. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 18:01 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 14,589 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-004436 · doc4.xml · derivative · entry 6 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 14,589 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each PRSU represents the right to receive one ordinary share of Mylan N.V. The PRSUs were initially granted on February 17, 2016, subject to the attainment of previously established three-year performance goals and a vesting period. The PRSUs fully vested on February 19, 2019. F2 · derivative.expiration_date: Each PRSU represents the right to receive one ordinary share of Mylan N.V. The PRSUs were initially granted on February 17, 2016, subject to the attainment of previously established three-year performance goals and a vesting period. The PRSUs fully vested on February 19, 2019. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 18:01 UTC | Mylan II B.V. MYL · Entity 16217 | GrantPerformance Restricted Stock Units · Derivative | 14,589 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-004436 · doc4.xml · derivative · entry 5 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,589 Underlying: Ordinary Shares · 14,589 shares Expires not disclosed F2 · derivative.exercise_date: Each PRSU represents the right to receive one ordinary share of Mylan N.V. The PRSUs were initially granted on February 17, 2016, subject to the attainment of previously established three-year performance goals and a vesting period. The PRSUs fully vested on February 19, 2019. F2 · derivative.expiration_date: Each PRSU represents the right to receive one ordinary share of Mylan N.V. The PRSUs were initially granted on February 17, 2016, subject to the attainment of previously established three-year performance goals and a vesting period. The PRSUs fully vested on February 19, 2019. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 18:01 UTC | Mylan II B.V. MYL · Entity 16217 | Tax withholdingOrdinary Shares | 6,067 | $32.10 | $194,750.70 |
DisclosureSEC source: 0000899243-19-004436 · doc4.xml · nonDerivative · entry 2 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,873 F1 · shares: Represents withholding of ordinary shares for the tax liability associated with the vesting and settlement of the performance restricted stock units (PRSUs) granted on February 17, 2016. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 18:01 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 14,589 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-004436 · doc4.xml · nonDerivative · entry 1 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2019 Filed Feb 20, 2019 18:02 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 22,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-004301 · doc4.xml · derivative · entry 5 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 22,024 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 6,484 of the RSUs granted on February 17, 2016 vested on each of February 17, 2017 and February 17, 2018, and 22,024 vested on February 17, 2019. F4 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 6,484 of the RSUs granted on February 17, 2016 vested on each of February 17, 2017 and February 17, 2018, and 22,024 vested on February 17, 2019. Read SEC document |
| February 17, 2019 Filed Feb 20, 2019 18:02 UTC | Mylan II B.V. MYL · Entity 16217 | Tax withholdingOrdinary Shares | 8,834 | $31.84 | $281,274.56 |
DisclosureSEC source: 0000899243-19-004301 · doc4.xml · nonDerivative · entry 2 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,351 F3 · shares: Represents withholding of ordinary shares for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on February 17, 2016. Read SEC document |
| February 17, 2019 Filed Feb 20, 2019 18:02 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 22,024 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-004301 · doc4.xml · nonDerivative · entry 1 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 579,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: 122,992 ordinary shares were returned to the reporting person's direct beneficial ownership on December 12, 2018 in the form of a scheduled annuity payment under the terms of the grantor retained annuity trust to which the reporting person initially contributed 250,000 ordinary shares on September 5, 2017. F2 · balance_after: On October 23, 2018, the reporting person contributed 100,000 ordinary shares of Mylan N.V. to a grantor retained annuity trust of which the reporting person is the sole trustee and sole annuitant. Read SEC document |
| March 04, 2018 Filed Mar 6, 2018 20:27 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 35,532 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006551 · doc4.xml · derivative · entry 13 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 35,532 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Each PRSU represents the right to receive one ordinary share of Mylan N.V. The PRSUs were initially granted on November 17, 2015, subject to the attainment of previously established two-year performance goals and a vesting period. The PRSUs fully vested on March 4, 2018. F9 · derivative.expiration_date: Each PRSU represents the right to receive one ordinary share of Mylan N.V. The PRSUs were initially granted on November 17, 2015, subject to the attainment of previously established two-year performance goals and a vesting period. The PRSUs fully vested on March 4, 2018. Read SEC document |
| March 04, 2018 Filed Mar 6, 2018 20:27 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 5,264 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006551 · doc4.xml · derivative · entry 12 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 5,264 of the RSUs granted on November 17, 2015 vested on each of March 4, 2016, March 4, 2017, and March 4, 2018. F8 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 5,264 of the RSUs granted on November 17, 2015 vested on each of March 4, 2016, March 4, 2017, and March 4, 2018. Read SEC document |
| March 04, 2018 Filed Mar 6, 2018 20:27 UTC | Mylan II B.V. MYL · Entity 16217 | Tax withholdingOrdinary Shares | 14,977 | $40.97 | $613,607.69 |
DisclosureSEC source: 0000899243-18-006551 · doc4.xml · nonDerivative · entry 7 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,169 F4 · shares: Represents withholding of ordinary shares for the tax liability associated with the vesting and settlement of the performance restricted stock units (PRSUs) granted on November 17, 2015. Read SEC document |
| March 04, 2018 Filed Mar 6, 2018 20:27 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 35,532 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006551 · doc4.xml · nonDerivative · entry 6 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2018 Filed Mar 6, 2018 20:27 UTC | Mylan II B.V. MYL · Entity 16217 | Tax withholdingOrdinary Shares | 2,324 | $40.97 | $95,214.28 |
DisclosureSEC source: 0000899243-18-006551 · doc4.xml · nonDerivative · entry 5 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 513,614 F3 · shares: Represents withholding of ordinary shares for the tax liability associated with the vesting and settlement of a portion of the RSUs granted on November 17, 2015. Read SEC document |
| March 04, 2018 Filed Mar 6, 2018 20:27 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 5,264 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006551 · doc4.xml · nonDerivative · entry 4 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 515,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 20:27 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 12,395 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006551 · doc4.xml · derivative · entry 11 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,790 Underlying: Ordinary Shares · 12,395 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 12,395 of the RSUs granted on March 3, 2017 vested on March 3, 2018, and 12,395 will vest on each of March 3, 2019 and March 3, 2020. F7 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 12,395 of the RSUs granted on March 3, 2017 vested on March 3, 2018, and 12,395 will vest on each of March 3, 2019 and March 3, 2020. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 20:27 UTC | Mylan II B.V. MYL · Entity 16217 | Tax withholdingOrdinary Shares | 5,472 | $40.97 | $224,187.84 |
DisclosureSEC source: 0000899243-18-006551 · doc4.xml · nonDerivative · entry 3 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,674 F2 · shares: Represents withholding of ordinary shares for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on March 3, 2017. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 20:27 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 12,395 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006551 · doc4.xml · nonDerivative · entry 2 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 20:27 UTC | Mylan II B.V. MYL · Entity 16217 | GrantRestricted Stock Units · Derivative | 43,935 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006551 · doc4.xml · derivative · entry 10 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,935 Underlying: Ordinary Shares · 43,935 shares Expires not disclosed F6 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. The RSUs vest in three equal annual installments beginning on March 2, 2019. F6 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. The RSUs vest in three equal annual installments beginning on March 2, 2019. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 20:27 UTC | Mylan II B.V. MYL · Entity 16217 | GrantEmployee Stock Option - Right to Buy · Derivative | 71,600 | $0.00 Strike: $40.97 | $0.00 |
DisclosureSEC source: 0000899243-18-006551 · doc4.xml · derivative · entry 9 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,600 Underlying: Ordinary Shares · 71,600 shares Expires 2028-03-02 F5 · derivative.exercise_date: 23,867 of the options will vest on March 2, 2019, 23,866 will vest on March 2, 2020, and 23,867 will vest on March 2, 2021. The options expire on March 2, 2028. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 20:27 UTC | Mylan II B.V. MYL · Entity 16217 | SaleOrdinary Shares | 50,000 | $40.91 | $2,045,695.00 |
DisclosureSEC source: 0000899243-18-006551 · doc4.xml · nonDerivative · entry 1 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,751 F1 · price: Represents the weighted average price of the reporting person's disposition of 50,000 shares in transactions ranging from $40.78 to $41.13. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ordinary shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 18:38 UTC | Mylan II B.V. MYL · Entity 16217 | GrantPerformance Restricted Stock Units · Derivative | 35,532 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-005373 · doc4.xml · derivative · entry 1 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,532 Underlying: Ordinary Shares · 35,532 shares Expires not disclosed F1 · derivative.exercise_date: Each Performance Restricted Stock Unit (PRSU) represents the right to receive one ordinary share of Mylan N.V. The PRSUs were initially granted on November 17, 2015, subject to the attainment of previously established two-year performance goals and a vesting period. The PRSUs will fully vest on March 4, 2018. F1 · derivative.expiration_date: Each Performance Restricted Stock Unit (PRSU) represents the right to receive one ordinary share of Mylan N.V. The PRSUs were initially granted on November 17, 2015, subject to the attainment of previously established two-year performance goals and a vesting period. The PRSUs will fully vest on March 4, 2018. Read SEC document |
| February 17, 2018 Filed Feb 21, 2018 18:37 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 6,484 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-004917 · doc4.xml · derivative · entry 4 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,024 Underlying: Ordinary Shares · 6,484 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 6,484 of the RSUs granted on February 17, 2016 vested on each of February 17, 2017 and February 17, 2018, and 22,024 will vest on February 17, 2019. F3 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 6,484 of the RSUs granted on February 17, 2016 vested on each of February 17, 2017 and February 17, 2018, and 22,024 will vest on February 17, 2019. Read SEC document |
| February 17, 2018 Filed Feb 21, 2018 18:37 UTC | Mylan II B.V. MYL · Entity 16217 | Tax withholdingOrdinary Shares | 2,588 | $42.14 | $109,058.32 |
DisclosureSEC source: 0000899243-18-004917 · doc4.xml · nonDerivative · entry 2 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 553,751 F1 · shares: Represents withholding of ordinary shares for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on February 17, 2016. Read SEC document |
| February 17, 2018 Filed Feb 21, 2018 18:37 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 6,484 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-004917 · doc4.xml · nonDerivative · entry 1 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2017 Filed Jun 9, 2017 18:16 UTC | Mylan II B.V. MYL · Entity 16217 | SaleOrdinary Shares | 25,000 | $40.00 | $1,000,000.00 |
DisclosureSEC source: 0000899243-17-015994 · doc4.xml · nonDerivative · entry 1 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 799,855 F1 · security: This sale of ordinary shares was executed pursuant to a 10b5-1 trading plan executed on May 16, 2017. Read SEC document |
| March 04, 2017 Filed Mar 7, 2017 19:16 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 5,264 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006734 · doc4.xml · derivative · entry 5 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,264 Underlying: Ordinary Shares · 5,264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. One-third of the RSUs granted on November 17, 2015 vested on each of March 4, 2016 and March 4, 2017, and the remainder of this award will vest on March 4, 2018. F4 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. One-third of the RSUs granted on November 17, 2015 vested on each of March 4, 2016 and March 4, 2017, and the remainder of this award will vest on March 4, 2018. Read SEC document |
| March 04, 2017 Filed Mar 7, 2017 19:16 UTC | Mylan II B.V. MYL · Entity 16217 | Tax withholdingOrdinary Shares | 1,682 | $45.18 | $75,992.76 |
DisclosureSEC source: 0000899243-17-006734 · doc4.xml · nonDerivative · entry 2 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 824,855 F1 · shares: Represents withholding of ordinary shares for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on November 17, 2015. Read SEC document |
| March 04, 2017 Filed Mar 7, 2017 19:16 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 5,264 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006734 · doc4.xml · nonDerivative · entry 1 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 826,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 19:16 UTC | Mylan II B.V. MYL · Entity 16217 | GrantRestricted Stock Units · Derivative | 37,185 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006734 · doc4.xml · derivative · entry 4 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,185 Underlying: Ordinary Shares · 37,185 shares Expires not disclosed F3 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. The RSUs vest in three equal annual installments beginning on March 3, 2018. F3 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. The RSUs vest in three equal annual installments beginning on March 3, 2018. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 19:16 UTC | Mylan II B.V. MYL · Entity 16217 | GrantEmployee Stock Option - Right to Buy · Derivative | 65,574 | $0.00 Strike: $45.18 | $0.00 |
DisclosureSEC source: 0000899243-17-006734 · doc4.xml · derivative · entry 3 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,574 Underlying: Ordinary Shares · 65,574 shares Expires 2027-03-03 F2 · derivative.exercise_date: These options vest in three equal annual installments beginning on March 3, 2018 and expire on March 3, 2027. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 19:00 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 6,484 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-004816 · doc4.xml · derivative · entry 3 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,508 Underlying: Ordinary Shares · 6,484 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 6,484 of the RSUs granted on February 17, 2016 vested on February 17, 2017, 6,484 will vest on February 17, 2018, and 22,024 will vest on February 17, 2019. F2 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 6,484 of the RSUs granted on February 17, 2016 vested on February 17, 2017, 6,484 will vest on February 17, 2018, and 22,024 will vest on February 17, 2019. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 19:00 UTC | Mylan II B.V. MYL · Entity 16217 | Tax withholdingOrdinary Shares | 2,057 | $42.05 | $86,496.85 |
DisclosureSEC source: 0000899243-17-004816 · doc4.xml · nonDerivative · entry 2 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 821,273 F1 · shares: Represents withholding of ordinary shares for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on February 17, 2016. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 19:00 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 6,484 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-004816 · doc4.xml · nonDerivative · entry 1 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 823,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.